ArticleCureus2025
A Rare Presentation of Sjögren's Syndrome With Hypokalemic Periodic Paralysis Treated Based on Renal Biopsy Findings.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypokalemic periodic paralysis (HPP) is a rare but significant manifestation of Sjögren's syndrome, often associated with distal renal tubular acidosis (dRTA). We report a case of a 60-year-old man with recurrent HPP due to severe hypokalemia. Despite the absence of sicca symptoms, serological testing and glandular function assessment confirmed the diagnosis of Sjögren's syndrome. Laboratory findings revealed marked hypokalemia, metabolic acidosis, and excessive urinary potassium excretion, consistent with dRTA. Renal biopsy showed a combination of hypokalemia-induced tubular damage and autoimmune tubulointerstitial nephritis (TIN). Potassium and bicarbonate supplementation improved symptoms initially, but persistent tubular dysfunction required a reassessment of the treatment strategy. Steroid therapy was introduced 14 months after renal biopsy due to ongoing tubular dysfunction, leading to significant renal function improvement and discontinuation of potassium supplementation. This case highlights the importance of considering Sjögren's syndrome in patients with unexplained hypokalemic paralysis, even in the absence of sicca symptoms. Furthermore, it underscores the potential role of renal biopsy in distinguishing hypokalemia-induced tubular dysfunction from autoimmune TIN, guiding treatment decisions in complex cases of Sjögren's syndrome with renal involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.